JoVE Logo

登录

需要订阅 JoVE 才能查看此.

An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors

-- views • 1:21 min

成績單

Take an anesthetized, immunocompromised mouse bearing a subcutaneous tumor xenograft that overexpresses a tumor-associated antigen or TAA.

Retroorbitally inject effector T cells expressing the luciferase enzyme.

Subcutaneously administer interleukin 2, a cytokine supporting effector T cell survival.

Retroorbitally inject bispecific antibodies engineered to contain binding sites for T and tumor cells. Allow the mouse to recover.

The antibodies and T cells reach the tumor via circulation.

The antibodies bind to CD3 on the T cells and TAA on the tumor cells, inducing the effector T cells to release toxins that initiate apoptosis in the tumor cells and release chemokines that recruit more T cells to the tumor.

Anesthetize the mouse, retroorbitally inject a luciferase substrate, and proceed to in vivo imaging.

Luciferase inside the T cells oxidizes the substrate, emitting bioluminescence.

Observe the bioluminescence over time. The magnitude of the signal correlates with the extent of T cell infiltration within the tumor.

article

01:24

An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors

相关视频

19 Views

JoVE Logo

政策

使用条款

隐私

科研

教育

关于 JoVE

版权所属 © 2025 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。